InChI=1S/C59H108N2O22/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-45(69)60-39(40(66)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2)38-78-56-51(74)50(73)53(44(36-64)80-56)81-57-52(75)55(49(72)43(35-63)79-57)83-59(58(76)77)33-41(67)47(61-46(70)37-65)54(82-59)48(71)42(68)34-62/h29,31,39-44,47-57,62-68,71-75H,3-28,30,32-38H2,1-2H3,(H,60,69)(H,61,70)(H,76,77)/b31-29+/t39-,40+,41-,42+,43+,44+,47+,48+,49-,50+,51+,52+,53+,54+,55-,56+,57-,59-/m0/s1 |
HWIQEEBMCAQYHW-LGDSWWPFSA-N |
O([C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2CO)OC[C@@H]([C@@H](/C=C/CCCCCCCCCCCCC)O)NC(CCCCCCCCCCCCCCCCC)=O)O)O)O)[C@]3(O[C@]([C@@H]([C@H](C3)O)NC(CO)=O)([C@@H]([C@H](O)CO)O)[H])C(=O)O |
|
tumour antigen
An antigenic substance produced in tumour cells, which triggers an immune response in the host.
|
|
View more via ChEBI Ontology
(2S,3R,4E)-3-hydroxy-2-(octadecanoylamino)octadec-4-en-1-yl 3,5-dideoxy-5-(2-hydroxyacetamido)-D-glycero-α-D-galacto-non-2-ulopyranonosyl-(2→3)-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside
|
(2S,3R,4E)-3-hydroxy-2-(stearoylamino)octadec-4-en-1-yl 3,5-dideoxy-5-(glycoloylamino)-D-glycero-α-D-galacto-non-2-ulopyranonosyl-(2→3)-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside
|
(5α,17α)-N-deacetyl-N-(hydroxyacetyl)-ganglioside GM3
|
ChemIDplus
|
1-O-(O-(N-(hydroxyacetyl)-α-neuraminosyl)-(2-3)-O-β-D-galactopyranosyl-(1-4)-β-D-glucopyranosyl)-ceramide
|
ChemIDplus
|
GM3-Neugc
|
ChemIDplus
|
HD3
|
ChemIDplus
|
HD3 ganglioside
|
ChEBI
|
N-glycoloyl-GM3
|
ChemIDplus
|
N-glycoloyl-GM3
|
ChemIDplus
|
N-glycolyl-neuraminyl-lactosyl-ceramide
|
ChemIDplus
|
Neugc(α2-3)gal(β1-4)glc(β1-1)cer
|
ChemIDplus
|
Neugc-GM3
|
ChemIDplus
|
69345-49-9
|
CAS Registry Number
|
ChemIDplus
|
1392562
|
PubMed citation
|
Europe PMC
|
19435393
|
PubMed citation
|
Europe PMC
|
19748674
|
PubMed citation
|
Europe PMC
|
25403557
|
PubMed citation
|
Europe PMC
|
3170597
|
PubMed citation
|
Europe PMC
|
3487502
|
PubMed citation
|
Europe PMC
|
7849044
|
PubMed citation
|
Europe PMC
|
|